The development of novel targeted anticancer agents has led to improved outcomes for many patients with various malignancies, but use of these agents may be associated with an increased risk of adverse events, including renal toxicity. Here, Camillo Porta and colleagues discuss current understanding of the renal toxic effects of targeted anticancer agents and the potential use of these agents in patients with renal disease.
- Camillo Porta
- Laura Cosmai
- Fabio Malberti
